e-learning
resources
Berlin 2001
Tuesday 25.09.2001
Mesothelioma, malignant pleural effusions and rare thoracic tumours
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Imaging of malignant pleural mesothelioma with fluordeoxyglucose positron emission tomography (FDG-PET)
A. Gröschel, D. Hellwig, K. Rentz, C. M. Kirsch, D. Ukena, G. W. Sybrecht (Homburg, Germany)
Source:
Annual Congress 2001 - Mesothelioma, malignant pleural effusions and rare thoracic tumours
Session:
Mesothelioma, malignant pleural effusions and rare thoracic tumours
Session type:
Thematic Poster Session
Number:
2701
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Gröschel, D. Hellwig, K. Rentz, C. M. Kirsch, D. Ukena, G. W. Sybrecht (Homburg, Germany). Imaging of malignant pleural mesothelioma with fluordeoxyglucose positron emission tomography (FDG-PET). Eur Respir J 2001; 16: Suppl. 31, 2701
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Imaging of complicated pneumonia: what is new?
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
Fluorodeoxyglucose positron emission tomography (FDG-PET) for detection and staging of bronchioloalveolar carcinoma
Source: Eur Respir J 2001; 18: Suppl. 33, 18s
Year: 2001
Integrated positron emission tomography-computed tomography (PET-CT) in the staging of lung cancer
Source: Annual Congress 2008 - New imaging modalities in the staging of lung cancer
Year: 2008
Clinicopathologic comparison of computed tomography and positron emission tomography scanning for mediastinal staging in NSCLC
Source: Annual Congress 2010 - Actual challenges in thoracic surgery
Year: 2010
Prognostic value of fluorine-18 fluorodeoxyglucose (18-FDG) positron emission tomography imaging in patients with non-small cell lung carcinoma
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
Positron emission tomography with 18F-fluoro-deoxyglucose (FDG-PET) for evaluation of indeterminate adrenal mass in patients with lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 596s
Year: 2002
Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the clinical diagnosis of lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 227s
Year: 2001
Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration
Source: Eur Respir J 2009; 33: 201-212
Year: 2009
Cytology, chest computed and positron emission tomography correlations in lung cancer malignant pleural effusion.
Source: International Congress 2018 – Mesothelioma and pleural malignancy: investigations and management
Year: 2018
Positron emission tomography (PET) and computed tomography (CT) in the assessment of the mediastinum for patients with presumed or established lung cancer
Source: Annual Congress 2008 - Lung cancer and other malignant diseases involving the lungs
Year: 2008
Positron emission tomography (PET) using
18
F-fluorodeoxyglucose (
18
FDG) can detect radiographically ”occult“ lung cancer (ROLC) in the central airways
Source: Eur Respir J 2001; 18: Suppl. 33, 18s
Year: 2001
Imaging the inflammatory activity of sarcoidosis
Source: Eur Respir J 2013; 41: 743-751
Year: 2013
(18)F-FDG positron emission tomography/computed tomography and pulmonary function in sarcoidosis
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013
Positron emission tomography in the diagnostic work-up of screening-detected lung nodules
Source: Eur Respir J 2015; 45: 501-510
Year: 2015
Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer
Source: Eur Respir J 2007; 29: 995-1002
Year: 2007
Imaging can replace mediastinoscopy: PRO
Source: Annual Congress 2005 - Lung cancer staging: not as simple as it seems?
Year: 2005
Assessing nodules detected in lung cancer screening: the value of positron emission tomography
Source: Eur Respir J 2015; 45: 314-316
Year: 2015
A comparison of fluorodeoxyglucose positron emission tomography (FDG-PET) and transthoracic needle biopsy (TNB) in the management of single pulmonary nodules (SPN)
Source: Annual Congress 2004 - Pneumothorax, chest drains
Year: 2004
Imaging can replace mediastinoscopy: CON
Source: Annual Congress 2005 - Lung cancer staging: not as simple as it seems?
Year: 2005
Quantitative
18
F-fluorodeoxyglucose positron emission tomography/computed tomography to assess pulmonary inflammation in COPD
Source: ERJ Open Res, 7 (3) 00699-2020; 10.1183/23120541.00699-2020
Year: 2021
Rebuttal
Source: Annual Congress 2005 - Lung cancer staging: not as simple as it seems?
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept